Healthcare Industry News: PDL BioPharma
News Release - July 29, 2009
EKR Therapeutics Announces the Appointment of Dave Iwanicki as Senior Vice President of Corporate DevelopmentBEDMINSTER, N.J.--(HSMN NewsFeed)--EKR Therapeutics, Inc., a specialty pharmaceutical company focused on acquiring, developing, and commercializing novel acute-care products, today announced the appointment of Dave Iwanicki as Senior Vice President, Corporate Development.
In this newly created position, Iwanicki will report to EKR co-founder and CFO, Richard DeSimone who noted, “Dave formerly served EKR as SVP, Commercial Operations, and thus possesses in-depth knowledge of both our day-to-day operations and long-term business objectives. This, plus his prior experience in pharmaceutical sales, marketing and deal transactions provide significant leverage in expanding EKR’s focus on identifying and evaluating new growth opportunities.”
“EKR has grown dramatically from a start-up to a cash-flow positive and debt free company in a relatively short time,” noted DeSimone. “We are well positioned to advance to the next phase of growth and are fortunate to have Dave onboard to spearhead our broadening corporate development activities.”
Howard Weisman, Chairman and CEO added, “I have known Dave for several years since we first collaborated in the successful growth of ESP Pharma.” In 2002, Weisman co-founded ESP with a business model similar to that of EKR and, within three years of start-up, ESP was acquired in a transaction valued at over $500 million. “Then, as now, Dave has demonstrated an exceptional wealth of pharmaceutical know how,” said Weisman. “The scope of his experiences should prove to be an invaluable asset in expanding the range and depth of EKR’s strategic growth plan.”
Dave Iwanicki will continue to serve on the executive leadership team of EKR in his new role with the company. Prior to joining EKR in early 2008, Dave was Vice President, Sales and Sales Operations and Corporate Officer for PDL BioPharma (NASDAQ: PDLI ). He served on the executive management team for the entire time he was at PDL and chaired the Commercial Opportunity Acquisition Team, acting as point person for PDL’s product divestitures including the $200 million cash sale of Bulsulfex to Otsuka Pharmaceuticals. Dave joined PDL in March 2005 upon the completion of that company’s acquisition of ESP Pharma, Inc., having served in the same capacity at ESP Pharma were he was part of the initial management team that commercialized ESP. Previously, Dave was employed for fifteen years by Eli Lilly and Company (NYSE:LLY ) where he held various sales, marketing and sales management positions. During his tenure with Lilly, Dave spent the last seven years in senior management positions in both retail and hospital sales. He was involved with the creation of Lilly’s cardiology business unit and cardiology specialty sales force and later helped create a diabetes specialty sales force of more than 510 sales representatives that launched three new products in three years and also assisted in creating a critical care sales force of 210 representatives. Dave received his BS degree in Business Administration from Western New England College.
About EKR Therapeutics
EKR Therapeutics is a privately held specialty pharmaceutical company focused on identifying, fostering and targeting the growth of novel acute-care hospital products to improve outcomes and patient quality of life. Backed by the strength of its management team, the dedication of its field force of product specialists and its commitment to excellence in customer service and medical education, EKR has been organized to be a class leader in commercializing products to address unmet and under-satisfied medical needs or to otherwise enhance the therapeutic value of acute-care products. For additional information about EKR visit the Company’s website at www.ekrtx.com.
Source: EKR Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.